Registration Number
0224U000141,
0121U112052
, R & D reports
Title
Development of the individual approaches to antiblastomic therapy in patients recovered from COVID-19.
popup.stage_title
Head
Krasnoselskyi Mykola V., Доктор медичних наук
Starenkyi Viktor P., Доктор медичних наук
Registration Date
03-01-2024
Organization
State Organization "Grigoriev Institute for Medical Radiologiy and Oncology of the National Academy of Medical Sciences of Ukraine"
popup.description2
Object of study: oncology patients who have experienced COVID-19. Object of study: determine the indications and optimal conditions for carrying out antiblastoma therapy in patients who have suffered from COVID-19, by individualizing the terms, treatment regimens and accompanying therapy, taking into account clinical and laboratory characteristics. Methods and apparatus: clinical-instrumental, immunological, hematological, morphological, Respons 910 biochemical photoelectric automatic analyzer, SUNRISE TECAN microplate photometer, Spirocom spirographic complex, CHISON 17 diagnostic ultrasonic device, XN-L550 automatic hematological analyzer. Theoretical and practical results: the theoretical result is the justification of a panel of clinical and immunological markers. A decrease in the number of eosinophils and monocytes in combination with changes in the subpopulation of lymphocytes (the number of CD3+HLA, CD4+, CD8+ and NK-cells) has been proven, which indicates suppression and exhaustion of the antitumor response. The practical result is conducting a survey of patients, developing criteria for choosing the date of initiation of antiblastoma therapy based on a score on the comorbidity scale, taking into account anamnesis, concomitant pathology, clinical and immunological data. Novelty: for the first time, a comorbidity scale was developed for cancer patients taking into account the risk of severe complications of COVID-19. As the criteria for the start of antiblastoma therapy and the appointment of appropriate accompanying therapy, the value of points was chosen, where below 5 points there is no need to change the terms of treatment and additional symptomatic therapy, 6-10 points are the need for additional accompanying therapy, more than 10 points are a contraindication to carrying out antiblastoma therapy. The effectiveness of implementation: no. Field of use: oncology, medical radiology.
Product Description
popup.authors
Artamonova Neonila Olehivna
Artiukh Serhii Volodymyrovych
Bilyi Oleksandr Mykolaiovych
Bilozor Nataliia Volodymyrivna
Bobrova Vladyslava Maksymivna
Vasyliev Leonid Leonidovych
Havrylenko Mykyta Vadimovich
Hladkykh Fedir Volodymyrovych
Hradil Hryhorii Ivanovych
Hromakova Inna Serhiivna
Zakrutko Anna Oleksandrivna
Kantsedal Olena Mykolaivnа
Kolomatska Viktoriia Volodymyrivna
Lysenko Viktoriia Mykolaivna
Lukashkova Olha Petrivna
Maistrenko Ihor Oleksandrovych
Niemykina Nadiia Viktorivna
Nasonova Alla Mykolaivna
Pidlisnyi Ruslan Anatoliiovych
Prokhorova Elvira Borysivna
Pushkar Olena Serhiivna
Pshyshevska Liudmyla Anatoliivna
Simonova-Pushkar Larysa Ivanivna
Samofalov Ihor Oleksandrovych
Svynarenko Andrii Viktorovych
Semenenko Kseniia Oleksandrivna
Slobodianiuk Olha Volodymyrivna
Sorochan Pavlo Pavlovych
Spuzyak Roman Mykhajlovych
Sukhina Olena Mykolayivna
Teslenko Iryna Mykolaivna
popup.nrat_date
2024-01-03
